

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This communication is being filed in response to the Examiner Interview Summary in this application having a mailing date of June 21, 2006. This submission is being timely filed.

Applicant would like to thank the Examiner and his supervisor, Examiner Wang, for the courtesy extended to David Rivas, M.D., Nadine Chien, Ph.D., Joe Kentoffio and Gary Connell at the personal interview on June 8, 2006. During the course of the interview, the prior art rejection was discussed. In particular, the *McMahon, et al.* reference was discussed in detail. Applicant's representatives made the following primary points:

(1) because the "as needed" use of paroxetine in *McMahon et al.* was not structured to avoid a priming dose effect, the study does not provide sufficient information for the skilled person to conclude that paroxetine is effective to treat premature ejaculation as needed in the absence of priming doses; and

(2) the *McMahon et al.* week 1 data cannot be relied upon by one skilled in the art as demonstrating an increase in ejaculatory latency by paroxetine over control.

Respectfully submitted,

SHERIDAN ROSS P.C.

By: /Darla G. Yoerg/

Darla G. Yoerg  
Registration No. 48,053  
1560 Broadway, Suite 1200  
Denver, Colorado 80202-5141  
(303) 863-9700

Date: July 21, 2006

J:\4220\781\PU\\$Submission of Statement.wpd